Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 10/20 | 0.47 |
| ▸ | MTOR | P42345 | 7/20 | 0.44 |
| ▸ | ATRIP | Q8WXE1 | 8/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738648 | 1.00 | ATR (0.47) | ATRMTORATRIPCHEK1PDCD1 | |
| SCHEMBL2487867 | 1.00 | ATR (0.47) | ATRMTORATRIPCHEK1PDCD1 | |
| SCHEMBL24269977 | 0.88 | ATR (0.47) | ATRMTORATRIPCHEK1PDCD1 | |
| SCHEMBL24269976 | 0.88 | ATR (0.47) | ATRMTORATRIPCHEK1PDCD1 | |
| SCHEMBL23848940 | 0.87 | ATR (0.55) | ATRMTORATRIPCHEK1PDCD1 | |
| SCHEMBL22160812 | 0.86 | ATR (0.44) | ATRMTORATRIPCHEK1PDCD1 | |
| SCHEMBL20797898 | 0.86 | ATR (0.44) | ATRMTORATRIPCHEK1PDCD1 | |
| SCHEMBL20797900 | 0.86 | ATR (0.44) | ATRMTORATRIPCHEK1PDCD1 | |
| SCHEMBL23848939 | 0.85 | ATR (0.53) | ATRMTORATRIPCHEK1PDCD1 | |
| SCHEMBL4205671 | 0.85 | FPR2 (0.39) | ATRMTORMALT1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116134022-B | ATR inhibitors and uses thereof | 上海德琪医药科技有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20230339927-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339927-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-10-26 | — | — | US | disclosed |
| CN-111655688-B | Substituted pyrrolopyridines as ATR inhibitors | 蓝谷制药有限责任公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116134022-A | ATR inhibitors and uses thereof | 上海德琪医药科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-20220227755-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | GREENGENE BIOSCIENCES INC. | 2022-07-21 | — | — | US | disclosed |
| EP-3679041-B1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | NEWAVE PHARMACEUTICAL INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11236089-B2 | Substituted pyrrolopyridines as ATR inhibitors | BLUEVALLEY PHARMACEUTICAL LLC (US) | 2022-02-01 | — | — | US | disclosed |
| CN-111655688-A | Substituted pyrrolopyridines as ATR inhibitors | 蓝谷制药有限责任公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3679041-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | BLUEVALLEY PHARMACEUTICAL LLC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20140018364-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-01-16 | — | — | US | disclosed |
| US-8552004-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-10-08 | — | — | US | disclosed |
| EP-2579877-A1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2013-04-17 | — | — | EP | disclosed |
| US-20130005725-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-8252802-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2012-08-28 | — | — | US | disclosed |
| WO-2011154737-A1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | WO | disclosed |
| US-20110306613-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| EP-2379530-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ASTRAZENECA (SE) | 2011-03-03 | — | — | US | disclosed |
| WO-2010073034-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339927-A1 | ATR INHIBITORS AND USES THEREOF | ATR, CHEK1, CHEK2 | ATR 1/4885MTOR 943/4885ATRIP 5/4885 |
| US-20220227755-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | ATR, RB1, ATRIP | ATR 1/4885MTOR 2109/4885ATRIP 3/4885 |
| US-20110306613-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | ATR 2609/4885MTOR 732/4885ATRIP 4540/4885 |
| US-20130005725-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | ATR 2609/4885MTOR 732/4885ATRIP 4540/4885 |
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ABCG2, CYP3A7, CYP2C19 | ATR 2253/4885MTOR 954/4885ATRIP 3336/4885 |
| US-11236089-B2 | Substituted pyrrolopyridines as ATR inhibitors | ATR, RB1, ATRIP | ATR 1/4885MTOR 2109/4885ATRIP 3/4885 |
| US-20140018364-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | ATR 2609/4885MTOR 732/4885ATRIP 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.